University of Twente Student Theses

Login

Cardioprotective drugs to inhibit DOXO-induced cardiotoxicity in combination with trastuzumab for HER2-positive breast cancer treatment

Rooij, R.N. de (2024) Cardioprotective drugs to inhibit DOXO-induced cardiotoxicity in combination with trastuzumab for HER2-positive breast cancer treatment.

[img] PDF
2MB
Abstract:Drug treatments, like anthracyclines with Trastuzumab for Her2-positive breast cancer, face withdrawal of promising treatments caused by the major side effect, cardiotoxicity. A 3D platform of µ-engineered heart tissues (3D-µEHTs) has created the possibility of receiving more insights into the mechanisms of cardiotoxicity. The 3D-µEHTs platform has been used for our research to investigate the contractility and sarcomere alteration of the existing anthracycline Doxorubicin and the antibody Trastuzumab. Our research has shown that Trastuzumab on itself was not cardiotoxic, even at a very high concentration. The combination of Trastuzumab with Doxorubicin, however, affects the contractility after one dose in only two days (D2, 1 µM DMSO Force of Contraction: 96,65 ± 1,38 µN, n=2; 1 µM DOXO and Trastuzumab Force of Contraction: 40,23 ± 3,75 µN, n=4). A more hopeful outcome are the signs of recovery of contractility at the end of the experiment. In addition, we performed a first in vitro experiment with a new cardioprotective drug which indicates no contractility protections in the 3D-µEHTs platform yet. This in vitro experiment has gathered information about existing and developing drug treatments for breast cancer, which affects millions of cancer patients who undergo treatment each year.
Item Type:Essay (Bachelor)
Faculty:TNW: Science and Technology
Subject:30 exact sciences in general, 42 biology, 44 medicine, 50 technical science in general
Programme:Biomedical Technology BSc (56226)
Link to this item:https://purl.utwente.nl/essays/99830
Export this item as:BibTeX
EndNote
HTML Citation
Reference Manager

 

Repository Staff Only: item control page